Login to Your Account



Financings Roundup

Avexa Raises $60.1M To Fund Phase III Trials Of HIV Agent

By Jim Shrine


Thursday, March 22, 2007
Australian biotechnology company Avexa Ltd. parlayed positive Phase IIb data on its lead HIV compound into a funding round that will total A$75 million (US$60.1 million). (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription